Who is this relevant for?
- Pharmaceutical buyers sourcing shortage medicines
- Hospitals managing supply risk
- Manufacturers evaluating UK market entry
- Distributors monitoring sourcing opportunities
The MHRA’s 2025 enforcement figures show the scale of illegal and unauthorised medicines still moving toward the UK market. The agency says it seized almost 20 million doses during the year, with a potential street value of nearly £45 million. It also blocked access to more than £2.1 million in assets linked to the trade.
For pharma operators, the message is straightforward. UK authorities are putting more pressure on illicit supply routes, online sales channels, and unlicensed manufacturing activity.
What the MHRA found
The largest seizure categories were sedatives, sleeping pills, painkillers, and erectile dysfunction medicines. The MHRA also seized more than 5,000 GLP-1 products marketed as weight-loss medicines.
The agency linked part of that activity to a warehouse in Northampton, where its Criminal Enforcement Unit said it dismantled an illicit manufacturing facility producing and distributing unlicensed weight-loss jabs.
The online channel remains a major focus. The MHRA said it worked with internet service providers to disrupt more than 1,500 websites and social media accounts involved in illegal sales, and removed more than 1,200 social media posts. It also cited work with eBay, where an AI tool blocked more than two million policy violations involving prescription-only and non-compliant OTC medicines before listings went live.
Why this matters for supply and sourcing
The release draws a clear line between unauthorised products and supply-chain risk. The MHRA states that medicines sold illegally online or outside authorised routes may contain the wrong dose, the wrong ingredient level, or other harmful ingredients. It also notes that unauthorised products have not been assessed for safety, effectiveness, or the quality and hygiene of manufacturing and distribution processes.
That matters for any organisation under pressure to secure supply. In categories facing high demand or opportunistic online trading, the enforcement trend points to tighter scrutiny of where product originates, how it is listed, and whether it is authorised for sale in the UK.
For distributors and buyers, this raises the compliance burden around supplier validation and channel controls. For manufacturers, it shows that the regulator is willing to act against both illegal online sellers and unlicensed production sites.
A stronger enforcement pattern
The MHRA said the 2025 total was up from 17 million doses seized in 2024. That suggests sustained enforcement activity rather than a one-off action.
The agency also highlighted financial investigation as part of its approach, using powers linked to proceeds of crime to trace, freeze, and confiscate assets. That broadens the pressure on illegal medicines supply beyond product seizure alone.
For companies operating in the UK medicines market, the practical takeaway is disciplined control over sourcing, distribution, and digital exposure. The enforcement record shows where the MHRA is spending its effort, and unlicensed medicines remain firmly in scope.